Irish drugs group Elan plunged 20.5 per cent to €3.42 on Friday, as European markets headed lower.

European regulators announced they were reviewing Tysabri, a multiple sclerosis drug produced by Elan and Biogen Idec, a US biotechnology group, on reports a brain disease linked to the drug had begun to appear more frequently.